Home・Список акций・Vaxcyte Inc

Vaxcyte Inc

Закрыт

СекторЗдравоохранение

57.9 -1.68

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

57.55

Макс.

58.07

Ключевые показатели
By Trading Economics
Доход	-74M -321M
Прибыль на акцию	-2.3
Сотрудники	507
EBITDA	-80M -315M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+96.88% upside

Дивиденды
By Acuity
Следующий отчет о доходах	11 авг. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-716M 7.7B
Предыдущая цена открытия	59.58
Предыдущая цена закрытия	57.9

Новостные настроения

By Acuity

50%

128 / 340 Рейтинг в Healthcare

Vaxcyte Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

7 авг. 2026 г., 21:01 UTC

Vaxcyte Inc shares are lower in after-market hours, continuing a weak trading session without any specific news to explain the decline.

6 авг. 2026 г., 20:03 UTC

News

Vaxcyte reports a net loss of $284.3 million for Q2. Shares are trading higher as the company anticipates key Phase 3 trial data in 2027.

5 авг. 2026 г., 19:16 UTC

Vaxcyte Inc. shares are higher today, aligning with broader market trends, despite no specific news identified. The stock remains near its one-month range low.

4 авг. 2026 г., 20:21 UTC

Vaxcyte Inc. shares are lower in after-market trading, remaining flat since Tuesday's close and positioned below its 20-day moving average.

3 авг. 2026 г., 19:46 UTC

Vaxcyte Inc's shares are lower today, continuing a decline since Friday. The stock is trading near the lower end of its one-month range.

31 июл. 2026 г., 19:56 UTC

Correlated Moves

Shares lower amid broader sector sentiment; SPDR S&P Biotech ETF declines.

30 июл. 2026 г., 18:52 UTC

Vaxcyte Inc's shares are higher today amid strong buying activity, reaching an intraday high but remain below the 20-day moving average.

29 июл. 2026 г., 18:23 UTC

Vaxcyte Inc is lower in Wednesday's session, breaking a trend of higher daily closes. No specific news was identified to explain the decline.

28 июл. 2026 г., 18:46 UTC

Vaxcyte Inc. shares are trading lower amid broader market trends and volatility, remaining below the 20-day moving average as bond yields decline.

27 июл. 2026 г., 19:46 UTC

Vaxcyte Inc shares are trading higher today, despite earlier declines and without specific company news. Broader market volatility is influenced by falling crude oil prices.

23 июл. 2026 г., 19:16 UTC

Vaxcyte Inc shares are lower today amid a broader decline in tech stocks following earnings reports from Alphabet and Tesla. No specific news was identified.

21 июл. 2026 г., 18:26 UTC

Vaxcyte Inc is trading higher today, continuing its advance since Monday's close. This movement occurs despite concerns over rising treasury yields and geopolitical tensions.

Сравнение c конкурентами

Изменение цены

Vaxcyte Inc Прогноз

Целевая цена

By TipRanks

96.88% рост

Прогноз на 12 месяцев

Средняя 114.33 USD 96.88%

Максимум 163 USD

Минимум 75 USD

Основано на мнении 7 аналитиков Wall Street, спрогнозировавших целевые цены для Vaxcyte Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

7 ratings

Покупка

Удержание

Продажа

Основано на мнении 7 аналитиков, присваивавших рейтинги акциям Vaxcyte Inc – Данные за последние 3 месяца.

Настроения

By Acuity

128 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Vaxcyte Inc

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.